Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Glioma 1Glioblastoma 1Brain Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 98Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 51Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Dianhydrogalactitol × Clear all
NCT01478178 2025-08-29

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Kintara Therapeutics, Inc.

Phase 1/2 Completed
55 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT03281681 2019-10-18

REPROVe

Kintara Therapeutics, Inc.

Phase 1/2 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡